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Cytokine storm can result from cancer immunotherapy or certain infections, including COVID-19. Though short-term immune-related adverse events are routinely described, longer-term immune consequences and sequential immune monitoring are not as well defined. In 2006, six healthy volunteers received TGN1412, a CD28 superagonist antibody, in a first-in-man clinical trial and suffered from cytokine storm. After the initial cytokine release, antibody effect-specific immune monitoring started on Day+10 and consisted mainly of evaluation of dendritic cell and T-cell subsets and 15 serum cytokines at 21 time-points over two years. All patients developed problems with concentration and memory; three patients were diagnosed with mild-to-moderate depression. Mild neutropenia and autoantibody production was observed intermittently. One patient suffered from peripheral dry gangrene, required amputations, and had persistent Raynaud’s phenomenon. Gastrointestinal irritability was noted in three patients and coincided with elevated γδT-cells. One had pruritus associated with elevated IgE levels, also found in three other asymptomatic patients. Dendritic cells, initially undetectable, rose to normal within a month. Naïve CD8+ T-cells were maintained at high levels whereas naïve CD4+ and memory CD4+ and CD8+ T-cells started high but declined over two years. T-regulatory cells cycled circannually and were normal in number. Cytokine dysregulation was especially noted in one patient with systemic symptoms. Over a two-year follow-up, cognitive deficits were observed in all patients following TGN1412 infusion. Some also had signs or symptoms of psychological, mucosal or immune dysregulation. These observations may discern immunopathology, treatment targets, and long-term monitoring strategies for other patients undergoing immunotherapy or with cytokine storm.   
Significance: 





Antibody or cell-based immunotherapeutics for cancer carry inherent risks of bystander immune activation, in addition to the effects of treating the intended tumor target [1-5]. The most severe of these immune-related adverse events (irAEs) are cytokine release syndrome (CRS) and neurotoxicity, most prominently described in patients treated with CAR-T-cells [6-11]. Treatment for CRS and associated neurotoxicity primarily targets IL-6, likely arising from monocytes or activated endothelium [1, 6, 11-17]. The site of cell activation is unclear, and may depend on disease burden, treatment target or how CRS is induced; antibody and cell therapies target tumor sites whereas infections, such as SARS-CoV-2 causing COVID-19, target points of pathogen entry, e.g. mucosal sites of the nasopharynx, lung and gastrointestinal tract [1, 11-19]. Immune checkpoint blockade induces irAEs during short-term follow-up of some patients with cancer, though robust immune biomarkers correlating with adverse effects of therapy are still being investigated [1, 4, 7, 20-25]. For long-term survivors who received immunotherapy or following CRS, immune monitoring is not yet standard of care, despite evidence that such patients may continue to experience secondary effects of treatment and irAEs [1, 3].






TGN1412 was produced by TeGenero AG (Wϋrzberg, Germany), manufactured by Boehringer Ingelheim (Germany), and the clinical trial was conducted by the contract research organization, PAREXEL International (Waltham, MA, USA) in their leased UK clinical trial site at Northwick Park Hospital, London, UK. Details of the clinical trial and the first 30 days of clinical follow-up have been reported [26]. The patients presented herein as A, B, C, D, E and F correlate with those previously identified as patients 2, 1, 5, 6, 4 and 3, respectively [26]. None of the authors of this work were involved with the conduct of the clinical trial or any of the pre-clinical testing of TGN1412. 

Patients and sources of data
All six patients were followed clinically (off-trial) and assessed as a cohort following the serious adverse event (SAE). Overall care and immune monitoring was coordinated and interpreted by the lead clinician (NP) who made appropriate referrals to subspecialists (CJM, MH, NA) or requests for specific immune monitoring tests as determined by clinical need. From six months post-event, all patients were assessed in a specialist cognitive disorders clinic by an expert neurologist (CJM) and psychiatrist (MH). All patient blood samples were anonymized and the scientists performing immunologic tests were not aware of clinical symptoms, signs, or clinical laboratory data (NEM, AJS, HOA-H, CLP, MK, AM and SCK). Blood was procured for immune, hematological and biochemical monitoring at each assessment by the lead clinician beginning 10 days after TGN1412 infusion and ending two years post-drug administration. In parallel, blood samples were obtained from healthy, male volunteers (n=24; after written informed consent) as comparative controls. All six TGN1412 trial participants were male, with median age of 29.5 years (range 19-34). The healthy control volunteers were male, with a median age of 30 years (range 19-42). None of the patients had a notable medical history and all were well during the two weeks preceding the clinical trial. Patients B and C were lost to immunological follow-up after 15 and 22 months, respectively. Patients provided written informed consent to data publication.

Immune monitoring
Immune monitoring started on Day+10 and was continued every 3-4 days for two weeks, then weekly for four weeks, then every four weeks for three months, and every six weeks to month eight (time-points 1-17). In the second year, patients were evaluated every three months (time-points 18-21). For the first six months, whole blood was assessed for T-cell and dendritic cell (DC) subset numbers, phenotype and function by measuring intracellular and serum cytokines (Fig. 1 and 2). After six months, tests were rationalized to those that were most informative. Correlates of immune function or potential were explored, including T-cell receptor Vβ repertoire, antigen recall assay with PPD, and T-cell homing for gut and skin based on expression of β7 integrin and cutaneous leukocyte antigen (CLA), respectively. These studies were conducted in a laboratory operating under GLP principles, undertaking exploratory research and using established protocols that were MIATA compliant (Supplementary MIATA information). The assays and reagents employed were previously validated and tested for performance during the course of standard general investigative research. 

Flow Cytometry
Whole blood was obtained by venipuncture into sodium-heparin Vacutainer™ tubes (Becton-Dickinson) and labeled with fluorochrome-conjugated monoclonal antibodies (mAb; Supplementary Table 1) for surface and intracellular cytokine detection, as previously described [28], and acquired on a FACSCalibur flow cytometer using CellQuest software (Becton-Dickinson). The Vβ repertoire kit was kindly donated by Beckman Coulter. The human FoxP3 staining kit (including anti-FoxP3 mAb; PCH101-APC) was from eBioscience (cat no.77-5776-40). Analyses were performed using WinList software (Verity Software House, Maine, USA) using off-line compensation to ensure objective analysis of data. Absolute cell numbers were determined by reference to a known quantity of Flow-Count™ Fluorospheres (Beckman Coulter, cat no. 7547053) added to each aliquot of cells immediately prior to acquisition.
Two DC subsets (Fig. 1) and major CD3+ T-cell subsets were identified (Fig. 2). The CD3+/CD8- (hereafter CD3+/CD4+) and CD3+/CD8+ T-cells were assessed for CD28+/CD25+ subsets, enriched for Tregs. Later analysis employed a mAb against FoxP3 (in lieu of CD28 mAb) to identify CD3+/CD4+ Tregs within the CD25+ population. This analysis verified that Tregs identified by CD28+/CD25+ contained the FoxP3+ subset, despite the absence of high CD25 expression (Fig. 2). DC maturation markers (CD80/CD86/CD40) were not informative and were removed from the protocol after four months (Day+133). At this time, patients were evaluated on two separate days, rather than all six on one day, allowing for faster laboratory processing of samples (with less cell death), but resulting in significant disparity in total cell numbers in certain T-cell subsets versus analyses prior to Day+133 for both the patient and healthy-control samples.

Cytokine Determinations
All sera (patient and healthy control) were stored at -80°C and thawed for re-aliquoting once prior to assessment. To ensure consistency, cytokines were assessed on a single run by one operator with a single multi-channel pipette (freshly calibrated) after a single freeze-thaw cycle for time points 1-19, and then a second run for the last two time points. Enzyme-linked immunosorbent assay (ELISA) with an ELx808TM absorbance microplate reader (BioTek Instruments Inc, USA) or a cytokine bead array was used for quantitative determination of cytokines as per manufacturer’s instructions (Supplementary Table 2). ELISA determinations were done in duplicate and on different plates in order to account for plate-to-plate variation. Method controls and normal control samples were included on each test plate in addition to standard controls for calibration. Normal controls and method controls were also included in cytokine bead array with samples tested once. 

Statistical analysis




TGN1412 affected all patients in four main areas: cognitive and psychiatric, autoimmune and inflammatory, immune mucosal barrier function, and alterations in immune cell subsets and cytokines in peripheral whole blood (Table 1; Supplementary Fig. 1). 

Cognitive and psychiatric effects 
The most consistent symptoms in all patients following the SAE were in memory and concentration. All patients reported subjective concentration and day-to-day memory problems, particularly for names. Although all patients scored within normal range on the Mini Mental State Examination, bedside cognitive examination and formal neuropsychometry performed between 6 and 12 months after the SAE revealed common deficits in verbal recall of information. Three patients exhibited poor verbal fluency suggestive of executive dysfunction. The patients initially showed some improvement, plateauing approximately 12 months after the event. These changes, in addition to the SAE itself, generated significant anxiety; psychotherapy was required in four. All patients underwent a comprehensive psychiatric assessment including a Structured Clinical Interview for Axis I Disorders (SCID-I). Three patients were diagnosed with mild-to-moderate depression; two of these, who required a prolonged stay in intensive care, were also diagnosed with post-traumatic stress disorder, (one also had associated panic disorder and agoraphobia). Five patients were able to return to work within two years. However, all noted that their previous work and everyday capabilities were limited compared with pre-trial due to decreased concentration, reduced memory and difficulty retaining information, persisting over two years.
Five patients had intermittent headaches that started several days after stopping steroids on Days+21-31 and became less frequent in the second year. The headaches were sharp, short-lasting and severe, often affecting the vertex of the head. All patients had unremarkable EEG and brain MRI. Five patients had normal FDG-PET brain scans (one patient declined). The eldest (patient A), whose memory and cognitive problems were most severe, had a lumbar puncture one year post-event which showed oligoclonal bands matched between serum and cerebrospinal fluid. The patients with headaches also had mild blurred distance vision; in patient C, whose symptoms were most severe, ophthalmologic testing did not reveal retinal disease or intraocular inflammation, although a change in contrast sensitivity of vision was noted; he declined further testing. Patient B had mild dry eyes and blepharitis with hypermetropia. Interestingly, patient D did not have headaches or blurred vision, yet was the most physically ill, requiring a prolonged stay in intensive care and a prolonged course of steroids.

Evidence of autoimmune phenomena and inflammation
Three patients (A, B, F) had mild and intermittent neutropenia (Fig. 3a). All patients reported intermittent arthralgias in knees, hands and back, and in four, were associated with low-titer anti-nuclear antibody (ANA; patient D), anti-cardiolipin antibody (ACA; patients A, D, E, F), intermittent equivocal rheumatoid factor (RF; patient A) or a positive anti-nuclear cytoplasmic antibody (ANCA) in perinuclear staining pattern directed against PR3 (patient A; also displayed mild neutropenia). These antibodies lasted less than five months at a time and did not correlate with changes in cell subsets or cytokine measurements. Complement levels were normal in all patients. 
Patient D was the most physically ill following TGN1412 infusion and suffered ischemic hands and feet of unclear cause. With improvement in his overall clinical condition, the extent of ischemia also improved (Fig. 4a, b). He underwent bilateral transmetatarsal amputation and removal of the terminal phalanges of both hands (one on the right and two on the left). Histopathologic examination showed no features of primary vasculopathy. The fingers of both hands displayed decreased pigmentation and, 10 months post-infusion, Raynaud’s phenomenon was noted in both hands that worsened during winter of the second year (18-24 months). Autoimmune antibody testing was consistently negative in this patient except for expression of a weak anti-nuclear antibody (ANA; 1:40 titer) in speckled pattern at seven and eight months and a low-titer anti-cardiolipin IgG antibody at eight and 24 months following infusion. 

Altered mucosal and immune barrier function 
Patients A, B and E had new gastrointestinal symptoms (diarrhea or frequent bowel motions) manifesting as intolerance to spicy foods and associated with a rise of γδT-cells in the blood (submitted). As the intolerance improved, this T-cell subset also declined. Because of the extent of symptoms in patient B, a full gastrointestinal work-up was undertaken including lactose intolerance test (normal), esophagogastroduodenoscopy, and colonoscopy; a 5mm sessile polyp in the proximal ascending colon showed inflammatory change. A cause for diarrhea was not found on random biopsies. 
All patients had skin erythema followed by desquamation to varying degrees and hair thinning in the days and weeks immediately following TGN1412 infusion. Increased skin dryness and sensitivity to sun exposure, chemicals and soaps was noted in three patients (A, C, D). Patient B suffered from ongoing pruritus over all skin areas; cetirizine could not be discontinued over two years due to recurrence of debilitating symptoms. He had a persistently increased level of IgE, and intermittent mild eosinophilia without other associated signs or symptoms of allergy (Fig. 3b, c).  Three other patients (D, E, F) also had persistently elevated IgE, without specific symptoms or seasonal correlation, two of whom also showed mild eosinophilia (E, F). Mast cells were absent from blood and gastrointestinal biopsies of patient B. Mobile, nontender and rubbery subcutaneous lumps were noted on the arms, and thorax of patient C. Three of these lumps were biopsied on two occasions, 14 months apart and were found to be benign lipomas or angiolipomas. Immune cells were not identified in these biopsies and a CT scan did not show significant adenopathy or lesions elsewhere.

Recovery kinetics of immune cell subsets and cytokines in peripheral blood
Both CD11c+ conventional and CD11c- plasmacytoid DC were initially depleted from the blood and recovered slowly over the first month towards normal (Fig. 5, Supplementary Fig. 2-4, a&b). Peripheral blood monocytes had recovered to normal by Day+10, unrelated to the recovery kinetics of DC [26]. Naïve CD4+ and CD8+ T-cells were detectable in low-to-normal range with a cyclical recovery pattern to normal over the first five months. Thereafter, naïve CD8+ T-cells persisted above normal and naïve CD4+ T-cells gradually declined (Fig. 5, Supplementary Fig. 2-4, c&d). Memory CD4+ and CD8+ T-cells were detected at higher-than-normal values and remained so until 9-12 months post-infusion, followed by a gradual decline in both to subnormal levels (Fig. 5, Supplementary Fig. 2-4, e&f). Activated CD4+ and CD8+ T-cells were initially high, returned to normal range over six months (Fig. 5, Supplementary Fig. 2-4, i&j) and followed the recovery pattern of DC and the slow decrease of memory T-cells (Supplementary Fig. 5). 
TGN1412 was a CD28 superagonist and preclinical studies indicated preferential stimulation of Tregs. The CD25+/CD28+ T-cell subsets, which include the CD4+ Tregs and corresponding CD8+ “Treg” population, were in normal range when monitoring started, decreased to low-to-normal levels over months 1&2 and continued to cycle circannually within the normal range over the two-year period (Fig. 5, Supplementary Fig. 2-4, g&h). This circannual cycle was also observed in healthy controls. Interestingly, the first peak of the CD8+ “Treg” subset occurred three months prior to that of the CD4+ “Treg” peak, but thereafter cycled together. At 15 months following infusion, the number of FoxP3+ Tregs was similar to that in healthy controls (data not shown). In vitro correlates of immune function indicated that T-cell proliferative responses to PPD antigen presentation, an antigen against which all six patients had previously been immunized, were similar to that of normal controls at seven months following infusion and T-cell Vβ repertoires were also normal in the total T-cell populations at 8.6 and 12.1 months following infusion (data not shown).




Intravenous infusion of the CD28 superagonist antibody, TGN1412, resulted in a cytokine storm heralded by high serum TNFα levels within an hour of infusion, with fever, delirium, headache, nausea, vomiting and diarrhea, early and rapidly progressive lung involvement with hypoxemia, disseminated intravascular coagulation, and depletion of lymphocytes and monocytes from the peripheral blood with slow and specific recovery kinetics, shared by all affected individuals [26]. All volunteers who received TGN1412 became patients who, on longer-term follow-up, had evidence of cognitive dysfunction, some also with psychological difficulties, headaches, autoimmune and mucosal barrier dysregulation in addition to immune cell subset and cytokine irregularities in peripheral blood. Although these features are now recognized in patients treated with checkpoint blockade and other cancer immunotherapies or in those who have suffered from CRS, it is usually unclear if the irAEs are related to other premorbid pathology or due to targeting of the underlying disease for which they required treatment [1, 3-6, 22-24]. In contrast, the significance of the cohort given TGN1412 is that they were all young and healthy, having been screened extensively for a first-in-man clinical trial, and had an immune stimulus that resulted in CRS simultaneously. The patients received similar and concurrent treatment, which enabled monitoring for irAEs and immunological biomarker assessment for clinical-pathologic correlation.
The cognitive symptoms were the most consistent feature shared by all patients. Where psychometric testing was performed, this confirmed initial deficits in recall and learning. The relationship of the headaches to this cognitive problem is unclear, although headache is now a well-described irAE [9]. The first headaches in all patients appeared within 90 minutes of infusion, coincident with delirium and an early rise in TNFα [30, 31]. In pre-clinical testing of TGN1412, specific fibrillary staining was seen in the cerebrum, cerebellum, spinal cord and pituitary gland of both humans and cynomolgus monkeys [32]. Since no adverse neurological observations were reported, it was concluded that this cross-reactivity with central nervous system (CNS) tissues may not be of major clinical relevance and that TGN1412 was not expected to adversely affect the CNS in humans. It is unclear whether the described difficulties in cognition and memory related to specific antibody targeting of the CNS, to the CRS that ensued [9, 17, 30], to the immune dysregulation that resulted [31, 33], or to the psychological impact of the events thereafter. 
Autoimmune colitis, vitiligo, and autoantibody production are now included in CTCAE grading of irAEs due to immunotherapy [1, 4, 6, 20, 22, 34]. It is still unknown if the patients presented here suffered from CRS due to ligation of CD28 on T-cells or another mechanism, such as monocyte or endothelial activation in the gastrointestinal tract or lungs, the first organs to be affected after intravenous infusion [11-15]. The etiology of autoimmune or inflammatory phenomena remains uncertain. It is notable that following the initial disappearance of blood mononuclear cells (coincident with CRS) there were different recovery kinetics of monocytes and DCs, consistent with the distinct lineages of these populations. The Raynaud’s phenomenon in patient D was directly related to the areas of resolved vascular injury, although the cause of the amelanotic areas of skin was less clear and may have been autoimmune in nature. Three patients with gastrointestinal symptoms had an associated increase in blood γδT-cells though without evidence of colitis on gut biopsies. Although Th17-cells were not specifically evaluated, all patients had IL-17 levels during immune reconstitution higher than those of normal controls, and a high level of IgE was found in four patients, suggesting a role for Th17-cells following TGN1412-induced CRS, and consistent with other reports of irAEs due to immunotherapy [23, 35, 36]. One patient with elevated IgE and debilitating pruritus was distinct in that he also had marked elevation of type-1 and -2 cytokines starting from three months post-infusion. This cytokine rise coincided with the decline in serum erythropoietin and, in the setting of hemoglobin levels and renal function similar to those of the other patients, may have indicated that erythropoietin was immunomodulatory in this setting [37, 38]. 
The initial appearance of increased activated T-cells and memory subsets was consistent with generalized immune activation immediately following the cytokine storm. The relatively few naïve T-cells during early reconstitution is consistent with programmed recovery in patients following chemotherapy [39, 40], immune checkpoint blockade [20, 24], or after infection [41, 42]. Contrary to that observed in response to viral infections and irAEs [20], the immune recovery following TGN1412-induced CRS was predominantly a CD4+ T-cell response. Since the patients are adults, the increase in naïve CD8+ T-cells over two years may suggest thymic-independent recovery [39], or the generation of a stable CD45RA+ memory cell subset from the CD45RO+ pool [43], also described in patients receiving checkpoint blockade [24]. This latter point may partially explain declining memory CD45RO+ T-cells over time. However, in light of the low-to-normal total CD4+ and CD8+ T-cells, this apparent decline could also be explained by the low point of normal T-cell circannual kinetics at the two-year follow-up [44]. 
Over two years, T-cell subsets displayed circannual kinetics [44, 45], especially noted in the CD25+/CD28+ subsets, incorporating Tregs. The Treg populations were found in normal numbers in patients relative to control values, and the kinetics of cell recovery over two years indicates that Treg numbers found in blood or tissues on single-point testing should be interpreted cautiously. Although TGN1412 was intended to target Tregs, the Tregs in the patients who received the antibody were normal in number. 
Physical, cognitive and immune abnormalities were observed in previously fit and healthy young men following infusion of TGN1412. CD28 on T-cells was the intended antibody target, yet the actual in vivo target in humans after intravenous infusion is unclear; these human data suggest that primary activation of monocytes or endothelium in the gut or lung were the primary targets. Clinical-pathologic correlation in these individuals resulted in valuable observations that may be instructive in understanding mechanisms of immune-induced pathologies, including those of checkpoint inhibitors, CAR-T cells, and infections such as COVID-19, known to target mucosal tissues and cause severe CRS [1, 5, 8, 19], and also provide a platform for long-term monitoring strategies for affected patients.
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Fig. 1 Gating strategy for peripheral blood conventional and plasmacytoid dendritic cells (DC) Viable whole blood cells (a – R1) were used as the starting population to identify HLA-DR+ DC (b – R2). By definition, DC lack expression of specific cell lineage markers (Lin: CD3, CD14, CD16, CD19 and CD34) and are routinely identified based on this HLA-DR+/Lin- expression. Relative to an isotype-matched control mAb (c inset), both major subsets of peripheral blood DC could be identified; conventional/CD11c+ cells (c – R3) and plasmacytoid/CD11c- cells (c – R4).
Fig. 2 Identification of peripheral blood T-cell subsets by four-color flow-cytometry Gating was based on viable whole blood cells (a – R1) wherein CD3+ T-cells (b – R2) were identified. Within the CD3+ R2 region, gating for absolute numbers of putative CD4+ (c – R3; CD8- cells) and CD8+ (c – R4) T-cells was based on the presence or absence of CD8 staining (CD8 is less susceptible than CD4 to down-regulation during T-cell stimulation used in the intracellular cytokine determination protocol [28]) and allowed for two more channels to be used for simultaneous positive and negative detection of other surface or intracellular proteins. Naïve CD45RA+/CD45RO- (d – R5) and memory CD45RA-/CD45RO+ (d – R6) T-cells were identified in each CD8- (putative CD4+) and CD8+ T-cell subset (isotype-matched control mAb are shown in the insets; d, e and f). Expression of the early activation marker CD69 was also quantified on CD4+ and CD8+ subsets of T-cells (e – R7). CD4+ and CD8+ populations of CD28+ T-cells were then further analysed for expression of CD25, a phenotype associated with regulatory T-cells (f – R8). Although Tregs can often be defined by a CD25hi population within the CD4+/CD25+ subset, a CD25hi population was not identified, possibly due to the FITC-conjugated anti-CD25 antibody used in this protocol.
Fig. 3 Two-year follow-up of relevant clinical parameters in the six patients Absolute neutrophil (a) and eosinophil counts (b) followed over the two-year period since TGN1412-induced cytokine storm show that three of the patients had mild intermittent neutropenia and three had intermittent eosinophilia. The latter three patients also had elevated levels of IgE (c), not always correlating with the elevated eosinophil counts. Horizontal dashed lines indicate the normal control reference ranges for each parameter.
Fig. 4 Ischemic and dermatologic changes in Patient D at three months following TGN1412-induced cytokine storm Areas of dry gangrene became fully demarcated at two-to-three months following the insult with vascular skin changes in the areas that became revigorated. Shown are changes prior to amputation of the ischemic digits in the (a) left hand and (b) right foot. Following amputations, he had persistent pain in both feet, some of which could be ascribed to phantom-limb pain, and had a sensory deficit which followed a glove-and-stocking distribution, consistent with the areas originally affected by ischemia during his critical illness. (c) During the patient’s critical care phase, an arterial line had been placed in the left radial artery and with recovery, a hyperkeratotic scar formed, 7cm x 4 cm in maximum dimensions, with faint satellite amelanotic lesions (1-3mm dimension, arrows). These lesions continued to improve with time, with regression of the scar and disappearance of the white satellite spots.
Fig. 5 Time course of changes in immune cell subsets during the first two years following infusion of TGN1412 Ongoing monitoring of T-cell and DC subsets in the peripheral blood have shown changes over time since the start of the monitoring period, 10 days following infusion of TGN1412. After the four-month time-point, significant disparity in numbers of certain T-cell subsets was observed, mostly due to shorter handling times for the samples and a resultant decrease in cell death. The data have been separated by a vertical dashed line to indicate this change; the entire two-year monitoring period is shown in a continuous time-course, but with a split in the data after the four-month change in protocol. The cell subsets measured were: (a) HLA-DR+/Lin-/CD11c+ conventional (“myeloid”) and (b) CD11c- plasmacytoid dendritic cells, (c) CD45RA+/CD45RO- naive CD4+ helper  and (d) CD8+ cytotoxic T-cells, (e) CD45RA-/CD45RO+ memory CD4+ helper and (f) CD8+ cytotoxic T-cells, CD25+/CD28+ “T-regulatory” CD4+ (g) and CD8+ T-cells (h) and CD69+ activated CD4+ (i) and CD8+ (j) T-cells (with the first four months shown in the inset for clarity of early events). Total CD3+ T-cells (k) indicates that although the total number of T-cells remained in the normal or high-normal range, the cell subsets making up the total changed over time. Whereas naïve CD8+ T-cells remained in the high-normal or higher range at the two-year follow-up, all other T-cells were below normal, especially in memory subsets and CD25+/CD28+ subsets which included Tregs. However, these low values at the two-year point were found at the expected trough of the circannual cycling pattern and may be normal. CD45RA-/CD45RO- T-cells were not observed at any time point during immune recovery. CD45RA+/CD45RO+ T-cells were observed intermittently throughout recovery in all patients and controls, albeit in small numbers (data not shown). Median and interquartile ranges for the cohort are shown for each time-point. Median and interquartile ranges for the normal controls are shown separately for the first four months and the remaining 18, indicated by the horizontal dashed lines on each figure. Total CD3+ (l), CD4+ (m) and CD8+ (n) T-cell subsets were also evaluated in the clinical laboratory by flow cytometry at the same time-points and served as an internal control. The total CD3+ cells correlated well between the research laboratory (k) and the clinical laboratory (l) and the total CD4+ and CD8+ T-cells remained in the low-normal range over two years.  Conventional units are shown in the y-axes (cells/mm3 = cells/μl) and is equivalent to 106cells/L in SI units.
Fig. 6 Cytokine levels in patient sera over two years following TGN1412-induced cytokine storm. Cytokine bead array or ELISA was used to measure cytokines (a) IFNγ, (b) IL-1β, (c) IL-12p70, (d) IL-8, (e) IL-4, (f) IL-5, (g) IL-17, (h) erythropoietin, (i) IL-2, (j) IL-10, (k) IL-6, (l) TNFα, (m) IL-11, (n) IL-15, (o) IL-23 and (p) sCD28 in all six patients for the two-year clinical follow-up. In comparison with the other five patients, patient B was clearly different in the cytokine response – he had a sustained increase in erythropoietin from day 10 following infusion until three months when IFNγ, IL-1β, IL-12p70, IL-8, IL-4, IL-5 and IL-17 all started to increase with another peak in these cytokines noted at month nine. He also had a worsening of his memory and cognitive symptoms and pruritus at month three following TGN1412 infusion. The level of IL-17 in the serum of patients over time was found to be different compared with that of matched controls (p<0.001) and with that of the serum concentrations in the same patients of IL-11, erythropoietin, IL-15, IL-23, sCD28, IFNγ, IL-8, IL-6 and IL-10 (p<0.001). There is no statistical difference between the patient data for IL-15, IL-11 and IL-23 and that of the normal controls. 
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